SHANGHAI – One-year-old Terns Pharmaceuticals will seed its pipeline with three candidates for nonalcoholic steatohepatitis (NASH), having acquired global development and commercialization rights from Eli Lilly and Co., of Indianapolis. Terns intends to take a China-first strategy for the development and registration of these candidates for liver disease while remaining open to global opportunities.